Brixadi: New FDA Approved Long Acting Buprenorphine for Opioid use Disorder.

On May 23, 2023: Braeburn announced that FDA has approved Brixadi, the new long-acting formulation of buprenorphine for the opioid use disorder. Now we will have two long-acting buprenorphine options: Sublocade & Brixadi. Sublocade was FDA approved in 2017 and now Brixadi received this FDA approval in 2023.
We have summarized Brixadi in the following sections:
1. Indication
2. How to Dose?
3. Injection Sites
4. Switching from Transmucosal Buprenorphine to Brixadi
5. Switching between weekly and monthly Brixadi
6. Brixadi Discontinuation
7. Common Side Effects
8. Warnings & Precautions
9. Drug Interactions
10. Brixadi REMS
psychiatryeducationforum.com/...